Uptake and Metabolism of Antibiotics Roseoflavin and 8-Demethyl-8-Aminoriboflavin in Riboflavin-Auxotrophic Listeria monocytogenes.
The riboflavin analogs roseoflavin (RoF) and 8-demethyl-8-aminoriboflavin (AF) are produced by the bacteria Streptomyces davawensis and Streptomyces cinnabarinus Riboflavin analogs have the potential to be used as broad-spectrum antibiotics, and we therefore studied the metabolism of riboflavin (vitamin B2), RoF, and AF in the human pathogen Listeria monocytogenes, a bacterium which is a riboflavin auxotroph. We show that the L. monocytogenes protein Lmo1945 is responsible for the uptake of riboflavin, RoF, and AF. Following import, these flavins are phosphorylated/adenylylated by the bifunctional flavokinase/flavin adenine dinucleotide (FAD) synthetase Lmo1329 and adenylylated by the unique FAD synthetase Lmo0728, the first monofunctional FAD synthetase to be described in bacteria. Lmo1329 generates the cofactors flavin mononucleotide (FMN) and FAD, whereas Lmo0728 produces FAD only. The combined activities of Lmo1329 and Lmo0728 are responsible for the intracellular formation of the toxic cofactor analogs roseoflavin mononucleotide (RoFMN), roseoflavin adenine dinucleotide (RoFAD), 8-demethyl-8-aminoriboflavin mononucleotide (AFMN), and 8-demethyl-8-aminoriboflavin adenine dinucleotide (AFAD). In vivo reporter gene assays and in vitro transcription/translation experiments show that the L. monocytogenes FMN riboswitch Rli96, which controls expression of the riboflavin transport gene lmo1945, is negatively affected by riboflavin/FMN and RoF/RoFMN but not by AF/AFMN. Treatment of L. monocytogenes with RoF or AF leads to drastically reduced FMN/FAD levels. We suggest that the reduced flavin cofactor levels in combination with concomitant synthesis of inactive cofactor analogs (RoFMN, RoFAD, AFMN, and AFAD) explain why RoF and AF contribute to antibiotic activity in L. monocytogenes IMPORTANCE: The riboflavin analogs roseoflavin (RoF) and 8-demethyl-8-aminoriboflavin (AF) are small molecules which are produced by Streptomyces davawensis and Streptomyces cinnabarinus RoF and AF were reported to have antibacterial activity, and we studied how these compounds are metabolized by the human bacterial pathogen Listeria monocytogenes We found that the L. monocytogenes protein Lmo1945 mediates uptake of AF and RoF and that the combined activities of the enzymes Lmo1329 and Lmo0728 are responsible for the conversion of AF and RoF to toxic cofactor analogs. Comparative studies with RoF and AF (a weaker antibiotic) suggest that the reduction in FMN/FAD levels and the formation of inactive FMN/FAD analogs explain to a large extent the antibiotic activity of AF and RoF.
Department of Biotechnology, Institute for Technical Microbiology, Mannheim University of Applied Sciences, Mannheim, Germany.
Andreas
A
Matern
Department of Bioprocess and Biotechnology, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara, Brazil.
Danielle
D
Pedrolli
Department of Biotechnology, Institute for Technical Microbiology, Mannheim University of Applied Sciences, Mannheim, Germany.
Stephanie
S
Großhennig
Laboratory for Molecular Infection Medicine Sweden (MIMS), Department of Molecular Biology, Umeå University, Umeå, Sweden.
Jörgen
J
Johansson
Department of Biotechnology, Institute for Technical Microbiology, Mannheim University of Applied Sciences, Mannheim, Germany m.mack@hs-mannheim.de.
Matthias
M
Mack
D000900:Anti-Bacterial Agents / Q000378:metabolism*; D052818:Autotrophic Processes; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D008089:Listeria monocytogenes / Q000235:genetics / Q000254:growth & development / Q000378:metabolism*; D012256:Riboflavin / Q000031:analogs & derivatives* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; C009191:roseoflavin; C023644:8-amino-8-demethylriboflavin; D012256:Riboflavin
Nucleic Acids Res. 2011 May;39(10):4235-48
21278422
Methods Mol Biol. 2014;1146:41-63
24764087
J Bacteriol. 2009 Jan;191(1):42-51
18931129
J Biol Chem. 1979 Oct 10;254(19):9551-7
226520
Microbiol Mol Biol Rev. 2011 Jun;75(2):321-60
21646432
Antimicrob Agents Chemother. 2000 Jan;44(1):88-96
10602728
PLoS One. 2012;7(6):e38244
22675529
Biochem Pharmacol. 2011 Dec 15;82(12):1853-9
21924249
Methods Mol Biol. 2014;1103:165-76
24318894
Genetika. 2012 Oct;48(10):1133-41
23270261
Nat Prod Rep. 2005 Jun;22(3):324-50
16010344
J Bacteriol. 2008 Mar;190(5):1546-53
18156273
Nucleic Acids Res. 2002 Jul 15;30(14):3141-51
12136096
Nucleic Acids Res. 2012 Sep 1;40(17):8662-73
22740651
Biochemistry. 2010 Oct 12;49(40):8748-55
20822113
RNA Biol. 2011 Jul-Aug;8(4):674-80
21593602
Int J Food Microbiol. 1997 Mar 18;35(1):91-5
9081230
FEMS Microbiol Rev. 2011 Jan;35(1):3-67
20497229
BMC Evol Biol. 2010 Oct 18;10:311
20955574
RNA Biol. 2009 Jul-Aug;6(3):276-80
19333008
Nat Struct Mol Biol. 2015 Jul;22(7):565-71
26052893
Curr Pharm Des. 2013;19(14):2552-60
23116394
FEBS J. 2011 Aug;278(15):2625-34
21635694
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14054-9
26494285
Nat Chem Biol. 2009 Aug;5(8):593-9
19561621
Acta Crystallogr D Biol Crystallogr. 2015 Dec 1;71(Pt 12):2526-42
26627660
Mol Syst Biol. 2012 May 22;8:583
22617957
Trends Biochem Sci. 2000 Mar;25(3):126-32
10694883
PLoS One. 2014 Nov 11;9(11):e112643
25386923
PLoS One. 2015 May 04;10(5):e0126124
25938806
J Mol Biol. 2010 Jul 9;400(2):218-30
20471397
FEBS J. 2016 Apr;283(8):1531-49
26913589
FEBS J. 2015 Aug;282(16):3230-42
25661987
J Antibiot (Tokyo). 1974 Jan;27(1):86-7
4843053
Biochemistry. 2013 Jun 25;52(25):4288-95
23713585
J Biol Chem. 2011 Nov 4;286(44):38275-85
21911488
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2534-9
23359690
J Bacteriol. 2007 Oct;189(20):7367-75
17693491
Angew Chem Int Ed Engl. 2016 May 10;55(20):6103-6
27062037
J Bacteriol. 2012 Dec;194(24):6818-27
23043000
Nucleic Acids Res. 2007 Jan;35(Database issue):D511-4
17202167
J Bacteriol. 1998 Feb;180(4):950-5
9473052
J Bacteriol. 2013 Sep;195(18):4037-45
23836860